The projected costs and benefits of a supervised injection facility in Seattle, WA, USA Academic Article uri icon

Overview

MeSH Major

  • Anti-Retroviral Agents
  • Antiretroviral Therapy, Highly Active
  • Delayed-Action Preparations
  • HIV Infections

abstract

  • This analysis suggests that a SIF program in Seattle would save lives and result in considerable health benefits and cost savings.

publication date

  • May 2019

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.drugpo.2018.12.015

PubMed ID

  • 30802842

Additional Document Info

start page

  • 9

end page

  • 18

volume

  • 67